Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001921094-23-000739
Filing Date
2023-10-05
Accepted
2023-10-05 16:31:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3892
  Complete submission text file 0001921094-23-000739.txt   5271
Mailing Address AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE MA 02139
Business Address
Cole Douglas G. (Reporting) CIK: 0001486373 (see all company filings)

Type: 144

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-38311 | Film No.: 231311739
SIC: 2836 Biological Products, (No Diagnostic Substances)